Findings highlight company’s approach is highly accurate for early-stage (I-II) detection: CRCs (91% sensitivity) and AA (54% sensitivity) at 92% specificity
Data offer hope for the future of blood-based early cancer detection
Universal Diagnostics (Universal DX), a bioinformatics and multi-omics company on a mission to transform cancer into a curable disease, today announced the results of a large international multi-cohort case-control study, which demonstrate that cell-free DNA methylation and fragmentation signals combined with machine-learning can be used to detect early-stage colorectal cancer (CRC) with 93% and pre-cancerous advanced adenomas (AA) with 54% sensitivity at 92% specificity.
The findings offer an optimistic glimpse into the future of early-stage CRC detection and cancer prevention via AA detection through a simple blood test. Such promising results within a large, international, prospectively collected patient cohort (U.S. and Europe) showcase the potential of Universal DX’s unique, proprietary technological platform Signal-X, which combines signal-enhancing NGS-Assay, biologically-relevant biomarkers, and fit-for-purpose computational biology.
“We have every reason to be positive about the future of early cancer detection based on these results,” said Christian Hense, COO at Universal DX. “Our research continues to build on itself, demonstrating in study after study that our unique combination of methylation and fragmentation signals and machine learning algorithm can detect colorectal cancer in its earliest stages with high accuracy. These findings on such a large sample set get us one giant step closer to a future where cancer can be a curable disease.”
